Home > Riviste > Minerva Endocrinology > Fascicoli precedenti > Articles online first > Minerva Endocrinology 2021 Nov 26

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Endocrinology 2021 Nov 26

DOI: 10.23736/S2724-6507.21.03605-8

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Acute pancreatitis caused by methimazole/carbimazole assumption: a case- series

Andrea A. SARRO 1 , Riccardo R. ESPOSITO 2, Angelica A. ZIBETTI 3, Alessandro A. PECERE 4

1 Department of Translational Medicine (DIMET), Università del Piemonte Orientale, Novara, Italy; 2 Independent Researcher, Todi, Perugia, Italy; 3 Institute of Legal Medicine, Università Magna Graecia di Catanzaro, Catanzaro, Italy; 4 Department of Pharmaceutical Science, Università degli Studi di Milano, Milano, Italy


PDF


INTRODUCTION: The World Health Organization (WHO) has listed 525 different drugs, that can lead to acute pancreatitis cases, as a medication side-effect. Among them, methimazole (MMI also known as thiamazole, the active form of carbimazole - CBZ) was included. We reported case reports of patients with overall features compatible with acute pancreatitis episodes following and presumably triggered by the exposure to MMI and its prodrug CBZ.
EVIDENCE ACQUISITION: A systematic search was performed on MEDLINE (PubMed) We included case reports of patients with overall features compatible with acute pancreatitis episodes following and presumably triggered by the exposure to MMI and its prodrug CBZ Data extraction and analysis were undertaken in duplicate.
EVIDENCE SYNTHESIS: We identified 7 case reports. The majority of patients were female and one patient was male. Mean age at baseline ranged from 18 to 80 years old. The average time, that elapses between the initiation of the therapy with MMI/CBZ and the onset of typical clinical signs and symptoms pathognomonic of acute pancreatitis, was 2-3 weeks.
CONCLUSIONS: Based on the data derived from these case reports, it could be considered the possibility of a potential association between MMI/CBZ exposure. Evidence is, however, limited and requires more studies of high quality to confirm this association.


KEY WORDS: Methimazole; Carbimazole; Acute pancreatitis; Case reports; Review

inizio pagina